Recent Updates
Recently added Catalysts

ACI-19764 at dose A1

Phase 1

Healthy Participants | Small molecule | Other |AC Immune SA|Last Updated: Sep 2, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment78

FDA Designations

No designations recorded

Clinical trial landscape

ACI-19764 at dose A1 · 1 trial · 3 indications

Phase 1 1
NCT07463196A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk FactorsHealthy Participants
RECRUITING114 Analytics
PHASE1RECRUITING
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
Healthy Participants
NCT07463196114
Unlock trial analytics

Study Endpoints

Primary Endpoints

Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely related, possibly related or probably related)
From first study treatment administration up to the end of the safety follow-up (i.e. 21 to 24 days after Day 4 for study Part A, 21 to 24 days after Day 17 for study Part B, and 21 to 24 days after Day 29 for study Part C)
Vital signs: Change from baseline in blood pressure
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
Vital signs: Change from baseline in respiratory rate
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
Vital signs: Change from baseline in pulse rate
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
Vital signs: Change from baseline in body temperature
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
ECG: Change from baseline in heart rate
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
ECG: Change from baseline in PR interval
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
ECG: Change from baseline in QRS interval
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
ECG: Change from baseline in QT interval
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
ECG: Change from baseline in QTcF interval
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
ECG: Change from baseline in QTcB interval
From baseline up to the end of the treatment and observation period for Parts A and B (i.e. Day 4 for study Part A and Day 17 for study Part B), and up to the end of the safety follow-up for Part C (i.e. 21 to 24 days after Day 29)
Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS)
From baseline up to the end of the treatment and observation period (i.e. Day 17 for study Part B and Day 28 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in plasma: Maximum observed concentration (Cmax), stratified by sex
From baseline to up to the end of the treatment and observation period (i.e. Day 4 for study Part A, Day 17 for study Part B, and Day 28 for study Part C)
Pharmacokinetic (PK) in plasma: Time to reach Cmax (tmax), stratified by sex
From baseline to up to the end of the treatment and observation period (i.e. Day 4 for study Part A, Day 17 for study Part B, and Day 28 for study Part C)
Pharmacokinetic (PK) in plasma: Area under the curve (AUC) from time zero to the last measured concentration above the limit of quantification (AUC 0-last)
From baseline to up to the end of the treatment and observation period (i.e. Day 4)

Applicable to study Part A only

Pharmacokinetic (PK) in plasma: AUC from time zero to infinity (AUC 0-infinity)
From baseline to up to the end of the treatment and observation period (i.e. Day 4)

Applicable to study Part A only

Pharmacokinetic (PK) in plasma: Terminal elimination half-life (t½)
From baseline to up to the end of the treatment and observation period (i.e. Day 4)

Applicable to study Part A only

Pharmacokinetic (PK) in plasma: Dose proportionality for Cmax and AUC 0-infinity
From baseline to up to the end of the treatment and observation period (i.e. Day 4)

Applicable to study Part A only

Pharmacokinetic (PK) in plasma: AUCtau (AUC of one dosing interval) after first and last study treatment administration, stratified by sex
From baseline to up to the end of the treatment period (i.e. Day 15 for study Part B and Day 29 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in plasma: Terminal elimination half-life (t½) after last study treatment administration, stratified by sex
From baseline to up to the last timepoint measured (i.e. Day 19 for study Part B and 21 to 24 days after Day 29 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in plasma: Average plasma concentration at steady state (Cavg,ss) during the last dosing interval, stratified by sex
From baseline to up to the end of the treatment period (i.e. Day 14 for study Part B and D28 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in plasma: Minimum plasma concentration at steady state (Cmin,ss) during the last dosing interval, stratified by sex
From baseline to up to the end of the treatment period (i.e. Day 14 for study Part B and D28 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in plasma: Trough (pre-dose) plasma concentrations (Ctrough), stratified by sex
From baseline to up to the end of the treatment period (i.e. Day 14 for study Part B and D28 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in plasma: Accumulation index (AI) for Cmax and AUCtau, stratified by sex
From baseline to up to the end of the treatment period (i.e. Day 14 for study Part B and D28 for study Part C)

Applicable to study Parts B and C only

Pharmacokinetic (PK) in CSF: Drug concentration at steady state (trough level capturing Cmin), stratified by sex
From baseline to Day 13

Applicable to study Part B2 and B3 only

Secondary Endpoints

Pharmacokinetic (PK) in plasma: Maximum observed concentration (Cmax) in fed state
From baseline up to the end of the treatment and observation period (i.e. Day 4) of the 2nd study period for the Food Effect group
Pharmacokinetic (PK) in plasma: Time to reach Cmax (tmax) in fed state
From baseline up to the end of the treatment and observation period (i.e. Day 4) of the 2nd study period for the Food Effect group
Pharmacokinetic (PK) in plasma: Area under the curve (AUC) from time zero to the last measured concentration above the limit of quantification (AUC 0-last), in fed state
From baseline up to the end of the treatment and observation period (i.e. Day 4) of the 2nd study period for the Food Effect group
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Placebo for study Part A (SAD)PLACEBO_COMPARATORParticipants receive a single oral dose of placebo
ACI-19764 at dose A1 for study Part A (SAD)EXPERIMENTALParticipants receive a single oral dose A1 of ACI-19764
ACI-19764 at dose A2 for study Part A (SAD) (optional)EXPERIMENTALParticipants receive a single oral dose A2 of ACI-19764
ACI-19764 at dose A3 for study Part A (SAD) (optional)EXPERIMENTALParticipants receive a single oral dose A3 of ACI-19764
ACI-19764 at dose A4 for study Part A (SAD) (optional)EXPERIMENTALParticipants receive a single oral dose A4 of ACI-19764
ACI-19764 at dose A5 for study Part A (SAD) (optional)EXPERIMENTALParticipants receive a single oral dose A5 of ACI-19764
ACI-19764 at dose A6 for study Part A (SAD) (optional)EXPERIMENTALParticipants receive a single oral dose A6 of ACI-19764
Placebo for study Part B (MAD)PLACEBO_COMPARATORParticipants receive multiple oral doses of placebo
ACI-19764 at dose B1 for study Part B (MAD)EXPERIMENTALParticipants receive multiple oral doses B1 of ACI-19764
ACI-19764 at dose B2 for study Part B (MAD) (optional)EXPERIMENTALParticipants receive multiple oral doses B2 of ACI-19764
ACI-19764 at dose B3 for study Part B (MAD) (optional)EXPERIMENTALParticipants receive multiple oral doses B3 of ACI-19764
Placebo for study Part CPLACEBO_COMPARATORParticipants receive multiple oral doses of placebo
ACI-19764 at dose C1 for study Part CEXPERIMENTALParticipants receive multiple oral doses C1 of ACI-19764

Interventions

NameTypeDescription
PlaceboDRUGPlacebo capsules matching ACI-19764 capsules
ACI-19764 at dose A1DRUGACI-19764 capsules at dose A1
ACI-19764 at dose A2DRUGACI-19764 capsules at dose A2
ACI-19764 at dose A3DRUGACI-19764 capsules at dose A3
ACI-19764 at dose A4DRUGACI-19764 capsules at dose A4
ACI-19764 at dose A5DRUGACI-19764 capsules at dose A5
ACI-19764 at dose A6DRUGACI-19764 capsules at dose A6
ACI-19764 at dose B1DRUGACI-19764 capsules at dose B1
ACI-19764 at dose B2DRUGACI-19764 capsules at dose B2
ACI-19764 at dose B3DRUGACI-19764 capsules at dose B3
ACI-19764 at dose C1DRUGACI-19764 capsules at dose C1
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Signed informed consent in a language understandable to the participant prior to any study-mandated procedure. 2. Healthy male (Parts A and B) or female (Part B) aged between 18 and 65 years (inclusive) at screening or, male or female with cardiovascular risk factors between ...

Countries:Netherlands
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMSep 2, 2026NCT07463196Enrollment: 78 → 114
MEDIUMSep 2, 2026NCT07463196Enrollment: 78 → 114
MEDIUMSep 2, 2026NCT07463196Enrollment: 78 → 114

Frequently asked questions about ACI-19764 at dose A1

What is ACI-19764 at dose A1?

ACI-19764 at dose A1 is an investigational small molecule being developed by AC Immune SA. It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied to assess its safety, absorption, elimination, and effects on the immune system.

Who makes ACI-19764 at dose A1?

AC Immune SA, traded under the ticker ACIU, is developing ACI-19764 at dose A1. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy participants.

What phase is ACI-19764 at dose A1 in?

ACI-19764 at dose A1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants.

What clinical trials is ACI-19764 at dose A1 in?

ACI-19764 at dose A1 is being studied in the Phase 1 clinical trial NCT07463196. This trial investigates the safety, absorption, elimination, and immune system effects of the drug in healthy participants and in participants with cardiovascular risk factors, including obesity and type 2 diabetes.

Is ACI-19764 at dose A1 being studied in healthy volunteers?

Yes, ACI-19764 at dose A1 is being studied in healthy participants. The Phase 1 clinical trial NCT07463196 enrolls healthy volunteers aged 18 years and older, and it also includes participants with obesity and type 2 diabetes mellitus.